229 related articles for article (PubMed ID: 31337967)
1. Huaier polysaccharide inhibits the stem-like characteristics of ERα-36
Hu B; Yan W; Wang M; Cui X; Hu Y; Chen Q; Zhang Y; Qi X; Jiang J
Int J Biol Sci; 2019; 15(7):1358-1367. PubMed ID: 31337967
[TBL] [Abstract][Full Text] [Related]
2. Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer.
Lin CC; Lo MC; Moody R; Jiang H; Harouaka R; Stevers N; Tinsley S; Gasparyan M; Wicha M; Sun D
Cancer Lett; 2018 Dec; 438():165-173. PubMed ID: 30227220
[TBL] [Abstract][Full Text] [Related]
3. Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer.
Li W; Yang H; Li X; Han L; Xu N; Shi A
Oncol Rep; 2019 Jan; 41(1):437-446. PubMed ID: 30365081
[TBL] [Abstract][Full Text] [Related]
4. PAC down-regulates estrogen receptor alpha and suppresses epithelial-to-mesenchymal transition in breast cancer cells.
Al-Howail HA; Hakami HA; Al-Otaibi B; Al-Mazrou A; Daghestani MH; Al-Jammaz I; Al-Khalaf HH; Aboussekhra A
BMC Cancer; 2016 Jul; 16():540. PubMed ID: 27465411
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
[TBL] [Abstract][Full Text] [Related]
6. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2
Ly S; Anand V; El-Dana F; Nguyen K; Cai Y; Cai S; Piwnica-Worms H; Tripathy D; Sahin AA; Andreeff M; Battula VL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722905
[TBL] [Abstract][Full Text] [Related]
7. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
8. Both bulk and cancer stem cell subpopulations in triple-negative breast cancer are susceptible to Wnt, HDAC, and ERα coinhibition.
Sulaiman A; Sulaiman B; Khouri L; McGarry S; Nessim C; Arnaout A; Li X; Addison C; Dimitroulakos J; Wang L
FEBS Lett; 2016 Dec; 590(24):4606-4616. PubMed ID: 27859250
[TBL] [Abstract][Full Text] [Related]
9. Huaier aqueous extract suppresses human breast cancer cell proliferation through inhibition of estrogen receptor α signaling.
Wang X; Zhang N; Huo Q; Sun M; Lv S; Yang Q
Int J Oncol; 2013 Jul; 43(1):321-8. PubMed ID: 23686317
[TBL] [Abstract][Full Text] [Related]
10. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer.
Zhou L; Wang D; Sheng D; Xu J; Chen W; Qin Y; Du R; Yang X; He X; Xie N; Liu S; Zhang L
Theranostics; 2020; 10(5):2405-2421. PubMed ID: 32104513
[No Abstract] [Full Text] [Related]
11. Regulation of ERα-dependent breast cancer metastasis by a miR-29a signaling.
Lü J; Zhao Q; Guo Y; Li D; Xie H; Liu C; Hu X; Liu S; Hou Z; Wei X; Zheng D; Pestell RG; Yu Z
J Exp Clin Cancer Res; 2023 Apr; 42(1):93. PubMed ID: 37081505
[TBL] [Abstract][Full Text] [Related]
12. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
13. Effect of Huaier on Melanoma Invasion, Metastasis, and Angiogenesis.
Su D; Jiang B; Yang Y; Miao Y; Fu Q; Zhang F
Biomed Res Int; 2020; 2020():8163839. PubMed ID: 32596377
[TBL] [Abstract][Full Text] [Related]
14. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC).
Ma F; Li H; Wang H; Shi X; Fan Y; Ding X; Lin C; Zhan Q; Qian H; Xu B
Cancer Lett; 2014 Oct; 353(2):153-9. PubMed ID: 25130168
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness.
Lan J; Wei G; Liu J; Yang F; Sun R; Lu H
Theranostics; 2022; 12(6):2598-2612. PubMed ID: 35401817
[No Abstract] [Full Text] [Related]
16. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
Al-Dhfyan A; Alhoshani A; Korashy HM
Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
[TBL] [Abstract][Full Text] [Related]
17. Estrogen Receptor Mediates the Radiosensitivity of Triple-Negative Breast Cancer Cells.
Chen X; Ma N; Zhou Z; Wang Z; Hu Q; Luo J; Mei X; Yang Z; Zhang L; Wang X; Feng Y; Yu X; Ma J; Guo X
Med Sci Monit; 2017 Jun; 23():2674-2683. PubMed ID: 28570501
[TBL] [Abstract][Full Text] [Related]
18. miR-190 enhances endocrine therapy sensitivity by regulating SOX9 expression in breast cancer.
Yu Y; Yin W; Yu ZH; Zhou YJ; Chi JR; Ge J; Cao XC
J Exp Clin Cancer Res; 2019 Jan; 38(1):22. PubMed ID: 30658681
[TBL] [Abstract][Full Text] [Related]
19. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
[TBL] [Abstract][Full Text] [Related]
20. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the β-catenin signaling pathway.
Huang J; Yang B; Xiang T; Peng W; Qiu Z; Wan J; Zhang L; Li H; Li H; Ren G
Mol Nutr Food Res; 2015 Jun; 59(6):1063-75. PubMed ID: 25755089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]